ACMJ
Anatolian Current Medical Journal

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2718-0115
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Effect of different DMARD use on the frequency of urinary infection in patients with rheumatoid arthritis
Abstract
Aims: It is known that the susceptibility to infection in general is increased in Rheumatoid Arthritis (RA) patients, but there is not enough information about whether urinary tract infections in particular differ according to different disease-modifying antirheumatic drugs (DMARDs) groups. The aim of this study was to compare the frequency of urinary infection attacks and pathogens in urine cultures of patients with RA treated with different groups of DMARDs.
Methods: In this retrospective study, 76 patients using biologic DMARDs (bDMARDs) and 74 patients using conventional synthetic DMARDs (csDMARDs) among patients followed with a diagnosis of RA for at least 5 years who came for regular follow-ups at our department’s rheumatic diseases outpatient clinic were included. Patients with known immunodeficiency conditions, use of prednisolone (>7.5 mg), chronic renal failure, and renal pathologies were excluded from the study. The evaluation and follow-up records of the included patients between 01.01.2019 and 31.12.2022 were examined. Patients age, sex, medications, comorbidities, urine biochemistry, and urine culture results were recorded. Patients with pyuria detected by urine biochemistry were considered to have a urinary infection.
Results: The mean age of patients in the csDMARD group was 61.39±11.41 (37-87) and the mean age of patients in the bDMARD group was 58.68±11.42 (33-89) (p=0.149). The number of urinary infection attacks during the follow-up period was similar in both the groups (p =0.090). The positive culture rate was 23.21% in the bDMARD group and 7.5% in the csDMARD group (p = 0.072). Escherichia coli was detected in 81.8% and Pseudomonas aeruginosa was detected in 18.2% of the positive cultures in the bDMARD group. The pathogen in all positive cultures of the csDMARD group was Escherichia coli.
Conclusion: Although urinary infection and positive culture rates were higher in patients receiving bDMARDs, no statistically significant difference was observed between the groups.

Keywords : Rheumatoid arthritis, urinary tract infections, DMARD

Download Article


1. Jin J, Li J, Hou M, et al. A shifted urinary microbiota associatedwith disease activity and immune responses in rheumatoidarthritis. Microbiol Spectr. 2023;11(3):1-12.
2. Puntis D, Malik S, Saravanan V, et al. Urinary tract infectionsin patients with rheumatoid arthritis. Clin Rheumatol. 2013;32(3):355-360.
3. Bergmans BJM, Gebeyehu BY, van Puijenbroek EP, et al.Infections in biological and targeted synthetic drug use inrheumatoid arthritis: where do we stand? a scoping review andmeta-analysis. Rheumatol Ther. 2023;10(5):1147-1165.
4. Smolen JS, Landewé RBM, Bergstra SA, et al. EULARrecommendations for the management of rheumatoid arthritiswith synthetic and biological disease-modifying antirheumaticdrugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
5. Radu A-F, Bungau SG. Management of rheumatoid arthritis: anoverview. Cells. 2021;10(11):2857.
6. Furst DE. The risk of infections with biologic therapies forrheumatoid arthritis. Semin Arthritis Rheum. 2010;39(5):327-346.
7. Listing J, Gerhold K, Zink A. The risk of infections associatedwith rheumatoid arthritis, with its comorbidity and treatment.Rheumatol (Oxford). 2013;52(1):53-61.
8. Cipriani P, Berardicurti O, Masedu F, et al. Biologic therapiesand infections in the daily practice of three Italian rheumatologicunits: a prospective, observational study. Clin Rheumatol. 2017;36(2):251-260.
9. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinarytract infections: epidemiology, mechanisms of infection andtreatment options. Nat Rev Microbiol. 2015;13(5):269-284.
10. Jeong S, Jeon K, Lee N, Park MJ, Song W. Changing genotypicdistribution, antimicrobial susceptibilities, and risk factors ofurinary tract infection caused by carbapenemase-producingpseudomonas aeruginosa. Ann Lab Med. 2024;44(1):38-46.
11. Consani Fernández SA, Díaz Cuña CL, Fernández Rey L, RostánSellanes S, Maciel Oleggini G, Facal Castro JA. Infectionsin systemic autoimmune diseases. Reumatol Clín (Eng Ed.).2021;17(10):582-587.
12. Wang D, Yeo AL, Dendle C, Morton S, Morand E, Leech M.Severe infections remain common in a real-world rheumatoidarthritis cohort: a simple clinical model to predict infection risk.Eur J Rheumatol. 2021;8(3):133-138.
13. Huang WN, Chuo CY, Lin CH, et al. Serious infection ratesamong patients with select autoimmune conditions: a claims-based retrospective cohort study from Taiwan and the USA.Rheumatol Ther. 2023;10(2):387-404.
14. Sharma C, Keen H. Ten-year retrospective review of the incidenceof serious infections in patients on biologic disease modifyingagents for rheumatoid arthritis in three tertiary hospitals inWestern Australia. Intern Med J. 2019;49(4):519-525.
15. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, SymmonsDPM. Rates of serious infection, including site-specific andbacterial intracellular infection, in rheumatoid arthritis patientsreceiving anti-tumor necrosis factor therapy: Results from theBritish Society for Rheumatology Biologics Register. ArthritisRheum. 2006;54(8):2368-2376.
16. Listing J, Strangfeld A, Kary S, et al. Infections in patients withrheumatoid arthritis treated with biologic agents. ArthritisRheum. 2005;52(11):3403-3412.
17. He B, Li Y, Luo WW, et al. The risk of adverse effects of TNF-αinhibitors in patients with rheumatoid arthritis: a network meta-analysis. Front Immunol. 2022;13:1-16.
18. Dey M, Bechman K, Zhao S, et al. Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis ofsummary of product characteristic data. RMD Open. 2022;8(2):1-8.
19. Quach LT, Chang BH, Brophy MT, Thwin SS, Hannagan K,O’Dell JR. Rheumatoid arthritis triple therapy compared withetanercept: Difference in infectious and gastrointestinal adverseevents. Rheumatol (Oxford). 2017;56(3):378-383.
20. Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections inpatients with rheumatoid arthritis receiving tofacitinib versustumour necrosis factor inhibitors: results from the open-label,randomised controlled ORAL Surveillance trial. Ann Rheum Dis.2022;81(11):1491-1503.
21. Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalizedinfection associated with biologic agents in rheumatoid arthritispatients enrolled in medicare. Arthritis Rheumatol. 2016;68:56-66.
22. Bechman K, Halai K, Yates M, et al. British Society for RheumatologyBiologics Register for Rheumatoid Arthritis Contributors Group;Hyrich KL, Galloway JB. Nonserious Infections in PatientsWith Rheumatoid Arthritis: Results From the British Societyfor Rheumatology Biologics Register for Rheumatoid Arthritis.Arthritis Rheumatol. 2021;73(10):1800-1809.
23. Chiu YM, Chen DY. Infection risk in patients undergoingtreatment for inflammatory arthritis: non-biologics versusbiologics. Expert Rev Clin Immunol. 2020;16(2):207-228.
24. Foxman B. The epidemiology of urinary tract infection. Nat RevUrol. 2010;7(12):653-660.
25. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L,Descalzo MA, Gómez-Reino JJ. Infecciones en pacientes tratadoscon antagonistas del factor de necrosis tumoral: incidencia,etiología y mortalidad en el registro BIOBADASER. Med Clin(Barc). 2011;137(12):533-540.
Article available in :
Volume 6, Issue 1, 2024
Page : 38-43
https://doi.org/10.38053/acmj.1377233
Article Information
Received : 17 Eki 2023
Accepted : 08 Ara 2023
Published : 15 Oca 2024
Corresponding Author :

Sevda Adar: Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkiye

[email protected]
Citation : Adar S, Taşgın MR, Dündar Ü, et al. Effect of different DMARD use on the frequency of urinary infection in patients with rheumatoid arthritis. Anatolian Curr Med J. 2024;6(1):38-43.

Read: -31
Cited: 0
Download : 173
_Footer